SCHEMBL956967

SCHEMBL956967

CC[C@@H](c1ccc(Br)cc1)N(C(=O)O)C(C)CC(=O)c1ccc(F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.41
MEN1 O00255 3/20 0.38
RAD52 P43351 1/20 0.37
ATM Q13315 1/20 0.36
PTPN1 P18031 1/20 0.36
HTR7 P34969 1/20 0.36
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
HDAC9 Q9UKV0 1/20 0.35
HDAC5 Q9UQL6 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15355391 0.87 KMT2A (0.43) KMT2AMEN1RAD52ATMPTPN1
SCHEMBL15355390 0.87 KMT2A (0.43) KMT2AMEN1RAD52ATMPTPN1
SCHEMBL956964 0.77 L3MBTL1 (0.39) KMT2ARAD52PTPN1ALDH1A1LMNA
SCHEMBL959437 0.74 PRCP (0.30)
SCHEMBL956965 0.73 KMT2A (0.38) KMT2AMEN1RAD52ATMPTPN1
SCHEMBL957533 0.70 ALDH1A1 (0.45) KMT2ARAD52PTPN1ALDH1A1LMNA
SCHEMBL1859092 0.70 TRPM8 (0.41) KMT2AMEN1ALDH1A1LMNATRPM8
SCHEMBL3642295 0.70 LMNA (0.39) KMT2AMEN1RAD52ATMPTPN1
SCHEMBL3642290 0.70 LMNA (0.39) KMT2AMEN1RAD52ATMPTPN1
SCHEMBL3637292 0.68 NPC1 (0.47) KMT2AMEN1HTR7HDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110015157-A1 CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 Vitae Pharmaceuticals ,Inc. 2011-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015157-A1 CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD11B2, HSD3B1 KMT2A 4200/4885MEN1 2026/4885RAD52 4472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.